Carmine Therapeutics
Singapore - SingaporeBiotechnology
Focus: Carmine Therapeutics is a Singapore-based biotech company developing a novel drug delivery platform using red blood cell extracellular vesicles (RBCEVs) for nucleic acid therapeutics in cardiovascular and nephrology indications. The company is publicly listed with a focused pipeline in underexplored therapeutic areas.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Carmine Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Carmine Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Sodium-GLucose coTransporter-2 inhibitors
Sodium-GLucose coTransporter-2 InhibitorsExtra-vascular lung water measurements by ultrasound
Chronic Kidney DiseaseClinical Trials (1)
Help build intelligence for Carmine Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.